BindingDB logo
myBDB logout

103 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
27035422 46 Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.EBI Vrije Universiteit Brussel
27043173 47 Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.EBI Pfizer Inc.
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
26390077 42 Tactical Approaches to Interconverting GPCR Agonists and Antagonists.EBI University of Minnesota
25284251 12 Tritium-labelled isovaleryl-RYYRIK-NH2 as potential antagonist probe for ORL1 nociceptin receptor.EBI Kyushu University
25147603 39 Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol.EBI Pharmacokinetics
25147602 43 Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists.EBI Pharmacokinetics
25898137 61 C7-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.EBI University of Bath
25556095 32 A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety.EBI West Chester University
24973818 70 Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.EBI University of Bath
24761755 76 Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity.EBI University of Bath
24657054 66 Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.EBI Astraea Therapeutics, LLC.
24678969 44 Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold.EBI Centro de Investigaci�n Lilly
23582449 20 Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.EBI Institute of Organic Synthesis
23466604 36 Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.EBI Universit£ degli Studi di Siena
23623415 33 Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.EBI Astraea Therapeutics, LLC.
22541041 84 Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor.EBI Centro de Investigaci�n Lilly
19527931 19 Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.EBI University of Ferrara
19473027 21 Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.EBI National Institute of Neuroscienc
17490886 7 Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids.EBI University of Ferrara
21438532 13 Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography.EBI National Institute of Mental Health
22898529 58 Discovery of 1-(ß-amino substituted-ß-alanyl)-N,N-dimethylindoline-2-carboxamides as novel nonpeptide antagonists of nociceptin/orphanin FQ receptor: efficient design, synthesis, and structure-activity relationship studies.EBI Pfizer Inc.
20875743 90 Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI Pfizer Inc.
19879767 5 Spare interactions of highly potent [Arg(14),Lys(15)]nociceptin for cooperative induction of ORL1 receptor activation.EBI Kyushu University
19683449 116 Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.EBI Human BioMolecular Research Institute
19125610 82 Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug.EBI Pfizer Inc.
18624395 16 High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues.EBI University of Maryland
18468891 59 Identification of novel benzimidazole series of potent and selective ORL1 antagonists.EBI Banyu Tsukuba Research Institute
17483457 58 A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.EBI Abbott Laboratories
18068993 31 Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.EBI Kyushu University
17428659 192 Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.EBI Schering-Plough Research Institute
16814543 14 Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.EBI Tohoku Pharmaceutical University
16762550 101 4-Substituted-8-(1-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with superior pharmacological and pharmacokinetic parameters.EBI F. Hoffmann-La Roche Ltd
15380196 141 1,3-Dihydro-2,1,3-benzothiadiazol-2,2-diones and 3,4-dihydro-1H-2,1,3-benzothidiazin-2,2-diones as ligands for the NOP receptor.EBI Purdue Pharma LP
12431062 33 Probing opioid receptor interactions with azacycloalkane amino acids. Synthesis of a potent and selective ORL1 antagonist.EBI Universit£ de Montr£al
12431054 28 Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.EBI Purdue Pharma L. P.
11585444 295 From hit to lead. Analyzing structure-profile relationships.EBI F-59000 Lille
10753470 95 High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.EBI F. Hoffmann-La Roche Ltd.
8021929 13 Synthesis and delta-opioid receptor antagonist activity of a naltrindole analogue with a regioisomeric indole moiety.EBI University of Minnesota
14980696 47 Design and synthesis of novel small molecule N/OFQ receptor antagonists.EBI Purdue Pharma L.P.
14684324 27 The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.EBI SRI International
12372523 133 Synthesis and structure-activity relationships of aminoalkylazetidines as ORL1 receptor ligands.EBI Schering Plough Research Institute
21866885 71 Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.EBI University of Bath
21330016 96 Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor.EBI Istituto Superiore di Sanit£
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
19818611 100 Rapid access towards follow-up NOP receptor agonists using a knowledge based approach.EBI Schering-Plough Research Institute
19604695 49 Synthesis and biological evaluation of imidazole derivatives as novel NOP/ORL1 receptor antagonists: exploration and optimization of alternative pyrazole structure.EBI Banyu Tsukuba Research Institute
19564110 31 Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist.EBI Tsukuba Research Institute
19678644 52 Discovery of orally active 3-pyridinyl-tropane as a potent nociceptin receptor agonist for the management of cough.EBI Schering-Plough Research Institute
19537798 22 Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.EBI Tsukuba Research Institute
19339177 127 The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.EBI Schering-Plough Research Institute
19332374 84 Identification of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety.EBI Schering-Plough Research Institute
18990569 76 Structure-activity relationships of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the treatment of cough.EBI Schering-Plough Research Institute
18537234 55 A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K+ channel.EBI Tsukuba Research Institute
18448337 31 Novel ORL1-selective antagonists with oral bioavailability and brain penetrability.EBI Banyu Tsukuba Research Institute
17420123 219 Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.EBI Schering-Plough Research Institute
17289383 157 Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands.EBI Schering Plough Research Institute
17166723 141 Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties.EBI Organon Laboratories Ltd.
16876401 48 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity.EBI Jerini AG
16762548 37 Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of GlyT1 inhibitors: achieving selectivity against the mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors.EBI F. Hoffmann-La Roche Ltd
16757170 40 Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with improved metabolic stability.EBI F. Hoffmann-La Roche Ltd
16722631 87 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.EBI Predix Pharmaceuticals Ltd.
16632355 116 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor.EBI Johnson & Johnson Pharmaceutical Research and Development
16621546 54 Design, synthesis, and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists.EBI Banyu Tsukuba Research Institute
16451050 111 Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity.EBI Banyu Tsukuba Research Institute
16246561 90 Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperidines as GlyT1 antagonists with improved pharmacological profile.EBI F. Hoffmann-La Roche Ltd
16246557 75 Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors.EBI F. Hoffmann-La Roche Ltd
16153834 102 Preparation of 3-spirocyclic indolin-2-ones as ligands for the ORL-1 receptor.EBI Johnson & Johnson Pharmaceutical Research and Development
15664818 81 Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists.EBI Organon Laboratories Ltd
15454210 36 Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor.EBI Purdue Pharma L.P.
15225731 2 Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect.EBI Johnson and Johnson Pharmaceutical
15163178 70 A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.EBI SRI International
15027881 32 Structure-activity study of the ORL1 antagonist Ac-Arg-D-Cha-Qaa-D-Arg-D-p-ClPhe-NH2.EBI Vrije Universiteit Brussel
12951102 46 Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor.EBI Purdue Pharma L.P.
11689089 30 Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.EBI Tohoku Pharmaceutical University
11101358 24 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity.EBI Central Pharmaceutical Research Institute
10602690 36 Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
11546835 55 The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.BDB McGill University
15855355 2 Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.BDB Louisiana State University
15509719 17 [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.BDB Section of Pharmacology
15383632 15 Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.BDB Temple University
15054115 11 DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.BDB Purdue Pharma Discovery Research
12538838 14 Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.BDB Taisho Pharmaceutical Co.
11191833 15 Characterisation and comparison of novel ligands for the nociceptin/orphanin FQ receptor.BDB Leicester Royal Infirmary
9353393 5 Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.BDB Torrey Pines Institute for Molecular Studies
19398200 45 Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity.BDB Banyu Pharmaceutical Co.
19394217 14 2-Cyclohexylcarbonylbenzimidazoles as potent, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonists.BDB Banyu Pharmaceutical Co.
19447610 39 Discovery of novel arylpyrazole series as potent and selective opioid receptor-like 1 (ORL1) antagonists.BDB Banyu Pharmaceutical Co.
19041249 48 Discovery and structure-activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor like-1 (ORL1) antagonists.BDB Nippon Shinyaku Co.
19147350 264 Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands: part 2.BDB Schering-Plough Research Institute
18232652 84 Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists.BDB Istituto Superiore di Sanita